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Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of death
worldwide. The Modified Vaccinia Ankara (MVA) vaccine vector expressing the
mycobacterial antigen 85A (MVA85A) was demonstrated to be safe, although it did not
improve BCG efficacy, denoting the need to search for improved tuberculosis vaccines.
In this work, we investigated the effect of IL-12 DNA -as an adjuvant- on an Ag85A DNA
prime/MVA85A boost vaccination regimen. We evaluated the immune response profile
elicited in mice and the protection conferred against intratracheal Mtb H37Rv challenge.
We observed that the immunization scheme including DNA-A85A+DNA-IL-12/MVA85A
induced a strong IFN-γ production to Ag85A in vitro, with a significant expansion of
IFN-γ+CD4+ and IFN-γ+CD8+ anti-Ag85A lymphocytes. Furthermore, we also detected
a significant increase in the proportion of specific CD8+CD107+ T cells against Ag85A.
Additionally, inclusion of IL-12 DNA in the DNA-A85A/MVA85A vaccine scheme induced
a marked augment in anti-Ag85A IgG levels. Interestingly, after 30 days of infection with
Mtb H37Rv, DNA-A85A+DNA-IL-12/MVA85A vaccinated mice displayed a significant
reduction in lung bacterial burden. Together, our findings suggest that IL-12 DNA might
be useful as a molecular adjuvant in an Ag85A DNA/MVA prime-boost vaccine against
Mtb infection.
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INTRODUCTION
Tuberculosis (TB) continues to be one of the main global health problems. In fact, despite
the excellent progress of the Directly Observed Treatment (DOT) strategy, and affordable and
effective anti-TB treatments, the World Health Organization estimated 1.45 million deaths due
toMycobacterium tuberculosis (Mtb) infection in 2018 (World Health Organization, 2019). TB has
always been correlated with poverty, especially in low- and middle-income countries. However,
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the incidence of TB has increased even in industrialized
countries, mainly in vulnerable groups. Furthermore, the
strategies for TB control have been hampered by the Human
Immunodeficiency Virus (HIV) co-infection and the emergence
of drug-resistant Mtb strains. Therefore, developing a vaccine
capable of preventing Mtb infection would contribute to
controlling the TB epidemic.
The attenuated Mycobacterium bovis Bacillus Calmette-
Guérin (BCG) has been the only vaccine available to be used
in humans for almost 100 years. BCG is effective in protecting
against pulmonary and extrapulmonary TB in children up to
10 years old (Abubakar et al., 2013), but protection against the
pulmonary form of TB in adults remains highly controversial
(Hatherill et al., 2020).
Currently, there are 15 vaccines in clinical trial phase I, II,
or III (Home—ClinicalTrials.gov1). The promising vaccine
Modified Vaccinia Ankara (MVA) vector expressing the
mycobacterial antigen 85A (MVA85A) was particularly well-
tolerated in HIV-1 infected adults (Ndiaye et al., 2015) and
infants (Tameris et al., 2013). Unfortunately, the BCG/MVA85A
immunization scheme failed to provide protection in phase
IIb clinical trials including both neonates and adults (Tameris
et al., 2013; Ndiaye et al., 2015). One possibility regarding the
low efficacy of the MVA85A might be the restrictive replication
capacity of the MVA (Gilbert, 2013). Several strategies have
been explored in order to augment MVA immunogenicity.
Some of those strategies include heterologous prime/boost
protocols, the use of co-stimulatory molecules, the deletion of
viral immunomodulatory genes still present in the poxvirus
genome and the combined use of adjuvants (García-Arriaza and
Esteban, 2014). Therefore, protocols that enhance the immune
response induced by MVA85A might be useful to improve the
protection of TB vaccines.
Interleukin-12 (IL-12) is a heterodimeric cytokine that plays
an essential role in cellular and humoral immunity. Indeed,
IL-12 constitutes an important link between innate and adaptive
immunity (Gately et al., 1998; Trinchieri, 2003). IL-12 is a
pro-inflammatory cytokine produced by antigen-presenting cells
like dendritic cells (DCs) and macrophages. IL-12 regulates
T-cell and natural killer (NK) cell responses. The importance
of IL-12 during the host immune response against Mtb
infection has been demonstrated both experimentally and by the
increased susceptibility of humans deficient in the IL-12 pathway
(Trinchieri, 2003). Moreover, the use of IL-12 as an adjuvant
expressed from a plasmid vector in heterologous schemes has
been successfully explored (Gherardi et al., 2000, 2001, 2003;
Abaitua et al., 2006; Rodríguez et al., 2012; Kalams et al., 2013;
Maeto et al., 2014; Elizaga et al., 2018). Additionally, the immune
modulator role of IL-12 DNA plasmid when included in DNA
vaccines against Leishmania major (Tapia et al., 2003) and
Abbreviations: BCG, Bacillus Calmette-Guérin; ConA, Concanavalin A; IL-12,
interleukin-12; Mtb, Mycobacterium tuberculosis; MVA, Modified Vaccinia
Ankara; MVA85A, MVA expressing the mycobacterial antigen 85A; pCI, empty
pCI plasmid; pCI-Ag85A, pCI plasmid expressing Ag85A; pCI-IL12, pCI plasmid
expressing murine IL-12; TB, tuberculosis.
1https://clinicaltrials.gov/ (accessed June 19, 2020).
Hepatitis B Virus (Chow et al., 1998; Du et al., 2003) infections,
has been also evaluated (Hanlon et al., 2001). However, so far,
IL-12 has been scarcely used as an adjuvant in the context of
TB vaccines.
In the present work, we investigated the use of IL-12 as a
molecular adjuvant included in a particular DNA prime/MVA
boost vaccine schedule. Our findings indicate that IL-12 DNA
might be used to increase the host immune response generated
by MVA85A againstMtb infection.
MATERIALS AND METHODS
DNA Vaccines
The plasmid pCI-neo (Promega) carrying the coding sequence of
Ag85A (pCI-Ag85A) was previously obtained at Dr. Calamante’s
laboratory at the IABIMO. The expression of Ag85A was
confirmed by Western blot using total protein extracts from
Baby hamster kidney (BHK-21) transfected cells and a polyclonal
anti-Ag85A antibody (Supplementary Figure 1).
The DNA plasmid expressing murine IL-12 (carrying the
p35 and p40 murine genes, pCI-IL12) (Gherardi et al., 2000;
Tapia et al., 2003) was kindly provided by Dr. Mariano Esteban
[Department of Molecular and Cellular Biology, National
Center of Biotechnology (CNB), Superior Council of Scientific
Investigations (CSIC), Madrid, Spain]. The correct expression
of the cytokine from the plasmid pCI-IL12 was corroborated
by quantifying IL-12 release in transfected cells’ supernatants.
Briefly, mouse 3T3 cells were transfected with 5 µg of
DNA-IL-12, using Lipofectamine (Invitrogen) according to the
manufacturer’s instructions. Forty-eight hours post-transfection,
1.8 × 105 pg/ml of IL-12 were detected by ELISA (optEIA, BD)
(Maeto, 2015).
Plasmids were purified from Escherichia coliDH5α with Endo
free Maxi-Prep purification kits (NucleoBond Xtra Maxi Plus EF,
Macherey-Nalgen) using pyrogen-free material.
Viruses
MVA85A encoding the complete sequence of Ag85A was
previously obtained at Dr. Calamante’s laboratory at IABIMO.
Viral stocks of MVA (expressing ovalbumin, an irrelevant
protein that does not overlap with Ag85A) and recombinant
MVA85A were propagated in chicken embryo fibroblasts,
clarified and titrated as described elsewhere (Cotter et al.,
2017). The expression of Ag85A was assessed by Western
blot using total protein extracts of chicken embryo fibroblasts
infected with MVA85A and a polyclonal anti-Ag85A antibody
(Supplementary Figure 1).
Antigen
In vitro stimulation of cells was performed with recombinant
Ag85A (BEI Resources, NIAID, NIH: Ag85A, Recombinant
Protein Reference Standard, NR-49427) resuspended in
phosphate-buffered saline (PBS; 1.37mM NaCl, 27mM KCl,
2mM KH2PO4, 80mM Na2H2PO4 anhydrous in water).
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Animals and Immunization
Six- to eight-week-old, pathogen-free BALB/c female mice
were purchased from the Central animal facility at the
University of Buenos Aires, School of Sciences. Animals
were housed in biosafety level 3 animal facilities at the
Operative Unit of the Biological Containment Center from the
National Administration of Laboratories and Health Institutes
“Dr. Carlos G. Malbrán” (UOCCCB-ANLIS), according to
approved proceedings (Approval code: DEP-20-00). Mice were
kept on ventilated racks and fed a standard ad libitum diet.
All experimental work was performed following International
Guidelines (European Parliament European Council, 2010;
National Research Council, 2011). All efforts were made to
minimize suffering of the animals.
Mice (4–5/group) received three intramuscular (i.m.)
administrations (separated by 2-week intervals) of plasmid DNA
(100 µg each time). Two weeks after the last immunization, mice
were intraperitoneally (i.p.) inoculated with 107 plaque-forming
units (PFU) of MVA. DNA vaccine vectors were diluted in
sterile PBS (final volume 50 µl). pCI-IL12 was administered
in conjunction with pCI-Ag85A. Sera and splenocytes were
collected 8 days after the last immunization. An empty pCI
plasmid was used as a DNA control. A recombinant MVA
expressing an irrelevant protein was employed as MVA control.
Mice were anesthetized, and blood samples were obtained by
cardiac puncture. Then blood was allowed to clot (4 h at room
temperature), centrifuged and sera were collected and stored
at−80◦C.
Splenocytes were isolated by routine methods. Briefly, the
spleens were gently disrupted through a 40-µm cell-strainer
(BD Biosciences). Subsequently, red blood cells were lysed,
and splenocytes were washed with RPMI (RPMI-1640 medium,
Gibco BRL) plus 5% (v/v) fetal bovine serum (FBS, Natocor).
Splenocytes were then resuspended at 10 × 106 cells/mL in
RPMIc [RPMI-1640 medium (Gibco BRL) supplemented with
2mM L-glutamine (Gibco BRL), 100 U/mL penicillin (Gibco
BRL), 0.1 mg/mL streptomycin (Gibco BRL), 10mM HEPES
(Gibco BRL), and 0.055mM β-Mercaptoethanol (Gibco BRL),
with 10% (v/v) FBS (Natocor)].
Intracellular Cytokine Staining (ICS)
Splenocytes were cultured (106 cells/wells) in 96-well U bottom
plates with RPMIc for 16 h, with or without Ag85A protein
(5µg/mL) plus anti-CD28 (1 ng/mL; BD Biosciences). In
some experiments, anti-CD107a and anti-CD107b (CD107a/b-
FITC; BD Biosciences) antibodies were added to Ag85A
stimulated cells to measure the cytotoxic activity of CD8T
lymphocytes (Betts et al., 2003). Cells stimulated during 5 h with
phorbol myristate acetate (PMA, 10 ng/mL, Sigma-Aldrich) plus
ionomycin (250 ng/mL, Sigma-Aldrich) were used as positive
controls. Monensin (2µM; Sigma-Aldrich) was added for the
last 5 h of culture. After washing, anti-CD4-APC and anti-
CD8-PerCP (BioLegend) antibodies were added for 30min.
Then, cells were fixed using 2% paraformaldehyde (PFA) and
permeabilizated with 0.5% (v/v) saponin (Sigma-Aldrich), 0.01%
(w/v) sodium azide, and 10% (v/v) FBS (Natocor) in PBS. Finally,
cells were stained using anti-IFN-γ-PE (Biolegend) for 30min
at 4◦C in the dark. Cells were acquired on a FACSAria II
flow cytometer (BD Biosciences). Isotype matched controls and
fluorescence minus one (FMO) controls were included in each
experiment. Data were analyzed using FlowJo v10 software (BD
Biosciences). Gates strategies and FACS examples are shown in
Figure 3.
Cytokine Production
Splenocytes were cultured at 106 cells/well (in triplicate wells)
in 96-well U bottom plates with RPMIc for 72 h with or
without recombinant Ag85A (5µg/mL). Cells stimulated with
Concanavalin A (ConA, 1 mg/mL) or PBS were used as positive
and negative controls, respectively. Culture supernatants were
stored at −80◦C until assayed. IFN-γ analysis was performed
using ELISA BD OptEIA set (BD Biosciences), according to the
manufacturer’s instructions.
Antibody Measurement
The presence of serum anti-Ag85A Abs was assayed by
ELISA. Ninety-six-well plates were coated with purified Ag85A
at 2.5µg/mL. Blockage was performed with 10% (v/v) FBS
in PBS-0.05% Tween 20. Samples (duplicates) were diluted
in blocking solution. Detection was performed using mouse
anti-IgG conjugated to peroxidase enzyme (Jackson Immuno
Research). TMB Peroxidase substrate (Sigma-Aldrich) was added
and the reaction was stopped by adding 2N H2SO4. Absorbance
was measured at 450 nm.
M. tuberculosis Challenge Infection
Mycobacterium tuberculosis H37Rv strain (Mtb H37Rv) was
grown in Middlebrook 7H9 broth (BD Biosciences) or in
7H10 agar (BD Biosciences), 0.2% (v/v) glycerol, and albumin-
dextrose-catalase-oleic acid supplement (BD Biosciences).
Cultures were harvested at exponential growing phase at 37◦C
and clumps were disaggregated by glass bead vortexing and
passage through a 25 Gauge needle. Bacteria were centrifuged
twice for 10min at 3,300× g and supernatants were diluted with
physiological solution. Finally, OD at 600 nm was determined.
Mtb H37Rv bacterial growth was performed in BSL3 security
cabinets at the UOCCCB-ANLIS.
Groups of five female BALB/c mice were intratracheally
inoculated with Mtb H37Rv (1 × 104 colony-forming unit
(CFU)/mice) as previously described (Revelli et al., 2012). Briefly,
animals were anesthetized with a mixture of ketamine and
xylazine (100 and 10 mg/kg, respectively), placed in supine
position over an acrylic backboard and the inoculum (20 µL)
was injected through the trachea with a Hamilton syringe
coupled to a blunt-ended probe. Mice were euthanized at 30
days post-infection by an intraperitoneal injection of a lethal
dose of ketamine and xylazine, and their spleens and lungs were
aseptically removed. The whole organs were homogenized in
2mL of sterile RPMI. Then, triplicates of serial dilutions were
plated in Middlebrook 7H10 agar for CFU counting.
Data Analysis
The quantitative data were expressed as mean ± standard
error of the mean (SEM). Analysis of variances (ANOVA)
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 September 2020 | Volume 10 | Article 581812
Morelli et al. IL-12 DNA in Ag85A Immunogenicity
FIGURE 1 | Experimental design. ROA, Route of Administration; i.m., intramuscular; i.p., intraperitoneally; pCI, pCI empty; pCI-IL12, pCI expressing IL-12;
pCI-Ag85A, pCI expressing Ag85A; MVA, recombinant MVA expressing an irrelevant protein; MVA85A, recombinant MVA expressing Ag85A.
followed by Holm-Sidak’s multiple comparison tests were used
to analyze differences between groups. For categorical variables,
the Fisher exact test was performed to compare proportions of
infected spleens. GraphPad Prism 6.0 (GraphPad Software) was
used for all statistical analysis. A p < 0.05 was considered as
statistically significant.
RESULTS
In order to evaluate the potential adjuvant role of IL-12
(expressed from a DNA vector) to increase the efficacy
of pCI-Ag85A and the heterologous pCI-Ag85A/MVA85A
immunization scheme, we immunized 6- to 8-week-old BALB/c
mice as shown in Figure 1. Briefly, each group of animals was
inoculated by the i.m. route with three doses of DNA vectors
separated by 2 weeks among them. In some groups, after 14
days of the last priming dose, mice were i.p. boosted with
107 PFU/animal of MVA85A. Mice from control groups were
immunized with empty DNA plasmid (pCI) and a recombinant
MVA expressing an irrelevant protein. Eight days after the last
dose, we analyzed the humoral and cellular immune responses
against Ag85A elicited by animals from the different vaccinated
groups.
To characterize the host cellular immune response generated
by vaccination during the acute phase, we isolated splenocytes
8 days after the last inoculation. Cells were then stimulated
in vitro with Ag85A, PBS (negative control), or ConA
(positive control) for 72 h. Considering that a type 1 immune
response generated after vaccination is critical for protection
against Mtb, we analyzed IFN-γ levels in culture supernatants
(Figures 2A,B). Mice immunized with pCI-Ag85A expressed
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FIGURE 2 | IL-12 DNA administration enhances the immune response of the host to Ag85A. (A,B) Splenocytes were stimulated in vitro with Ag85A (5µg/mL), ConA
or PBS for 72 h. IFN-γ production was then determined by ELISA. Each bar represents the mean of IFN-γ production (PBS subtracted) ± SEM. (C,D) Anti-Ag85A IgG
levels in mice serum were determined by ELISA. The samples were diluted (C) 1/100 and (D) 1/10,000 in PBS-10% fetal bovine serum. Each bar represents the mean
of OD 450nm ± SEM. Comparisons among groups were determined by one-way ANOVA followed by Holm-Sidak’s multiple comparison test. A value of p < 0.05 was
considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Results are representative of two independent experiments.
low levels of IFN-γ. However, a significant increase in the
amount of this cytokine was detected when pCI-IL12 was
co-administered to the animals. Furthermore, the highest
levels of IFN-γ were observed in mice that were boosted
with MVA85A (Figure 2A). As expected, splenocytes from
pCI-Ag85A, pCI-Ag85A+pCI-IL12, pCI-Ag85A/MVA85A, and
pCI-Ag85A+pCI-IL12/MVA85A mice produced significantly
higher IFN-γ levels in response to Ag85A stimulation as
compared to their controls. Interestingly, co-administration
of pCI-IL12 and pCI-Ag85A significantly augmented the
levels of IFN-γ, denoting the clear adjuvant effect of IL-12
(Figure 2B).
Although the relevance of antibodies in the protection against
Mtb is not clear, the humoral response cannot be ruled out
as a factor that contributes to Mtb containment. Protective
antibodies might promote and increase intracellular bacterial
death through phagocytosis mediated by FcR, and improve
the immune response via the rapid antigen adsorption and
processing. Therefore, we evaluated the levels of anti-Ag85A
IgG in serum. As shown in Figure 2C, we observed a slight
increment of anti-Ag85A IgG levels when pCI-IL12 was co-
administered with pCI-Ag85A. Nevertheless, MVA85A boost
induced a significant increase in anti-Ag85A IgG in serum of
vaccinated mice. Importantly, when we evaluated the effect of IL-
12 on the MVA boosted strategy, mice that received pCI-IL12
as an adjuvant displayed the highest levels of anti-Ag85A IgG
(Figure 2D).
Next, we investigated whether the use of IL-12 as an adjuvant
stimulated the production of IFN-γ by different populations of
T lymphocytes. To do this, 8 days after the last antigenic dose,
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FIGURE 3 | The co-administration of IL-12 DNA induced a strong cellular
immune response against the Ag85A in mice spleen. Splenocytes from
immunized mice were stimulated in vitro with PBS or recombinant Ag85A for
16 h. Then, IFN-γ production and CD107a/b surface expression were
determined by flow cytometry. (A) Gate strategy. CD4+ or CD8+ IFN-γ+ T
cells and CD8+CD107a/b+ T lymphocytes were identified by flow cytometry
first gating on lymphocytes by light scatter; then, gating on CD4+ and CD8+ T
cells; and finally, gating according to IFN-γ+ and CD107a/b+ expression using
the AND boolean gate tool from FlowJo v10 software. Each bar represents the
mean (PBS subtracted) of the (B) %CD4+ IFN-γ+ cells ± SEM, (C)
%CD8+ IFN-γ+ cells ± SEM, (D) %CD8+CD107a/b+ cells ± SEM, (E)
%CD8+CD107a/b+ IFN-γ+ cells ± SEM. Comparisons among groups were
determined by one-way ANOVA
(Continued)
FIGURE 3 | followed by Holm-Sidak’s multiple comparison test. A value of
p < 0.05 was considered statistically significant. n.s., non-significant
difference, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Results
are representative of two independent experiments. Representative dot plots
are shown for (F) % CD4+ IFN-γ+ T cells, (G) % CD8+ IFN-γ+ T cells, and (H)
% CD8+CD107a/b+ T lymphocytes (large quadrants). Controls (small
quadrants) are shown.
mice were sacrificed, and recovered splenocytes were stimulated
in vitro with Ag85A. We observed that pCI-Ag85A/MVA85A
immunization induced a marked augment in the percentage of
CD4+ and CD8+ IFN-γ+ T lymphocytes (Figures 3B,C). Even
more, when pCl-IL12 was co-administrated with pCI-Ag85A, a
significantly higher increase in the percentage of CD4+IFN-γ+
and CD8+ IFN-γ+ T cells was detected as compared to the
pCI-Ag85A animal group (Figures 3B,C).
Besides, in order to evaluate the cytotoxic potential of specific
CD8+ T cells expanded by the immunization, we incubated
splenocytes from the different immunized groups with Ag85A
plus anti-CD107 monoclonal antibody. As shown in Figure 3D,
pCI-Ag85A/MVA85A immunization induced the expression of
CD107a/b on CD8+ T lymphocytes. Importantly, this response
resulted significantly improved when IL-12 was included in the
immunization scheme (Figure 3D). Even more, the adjuvant
effect of IL-12 was also observed when the percentage of
CD8+IFN-γ+CD107a/b+ cells induced in immunized mice
was analyzed (Figure 3E). In conclusion, these results denote
that additional benefits of including IL-12 adjuvant in vaccine
formulations may be the expansion and activation of CD8+
cytotoxic T lymphocytes.
Considering our findings demonstrating that pCI-IL12
potentiates the anti-Ag85 systemic immune response induced
by pCI-85A/MVA85A vaccination, we next decided to evaluate
its efficacy against Mtb containment. For this, 4 weeks after
the last immunization (Figure 1), mice were intratracheally
infected with pathogenic Mtb H37Rv strain. After 30 days, the
number of CFU per lung and the presence of bacteria in spleen
were determined. As shown in Figure 4, pCI-Ag85A/MVA85A
vaccination slightly diminished the total CFU per lung as
compared to control animals. In contrast, by using pCI-IL12
during vaccination, a significant decrease in the number of
CFU per lung was observed as compared to animals that
did not receive the adjuvant (Figure 4A). In line with these
results, 75% of pCI-Ag85A/MVA85A vaccinated mice displayed
Mtb in their spleens, whereas only 25% of pCI-Ag85A+pCI-
IL12/MVA85A vaccinated animals presented bacteria in their
spleens (Figure 4B). These results suggest an association between
the increase in the cellular immune response and the protection
improvement in mice that received IL-12.
DISCUSSION
Nowadays, Mycobacterium bovis BCG displays 90% of
effectiveness in childhood tuberculous meningitis and miliary TB
(Mangtani et al., 2014). However, regarding pulmonary TB, the
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FIGURE 4 | pCI-IL12 improves control of Mtb H37Rv in mice. Immunizations were performed as described above. Four weeks after the last immunization, mice were
challenged with Mtb H37Rv via intratracheal route (n = 4–5/group). Mice were sacrificed 4 weeks after challenge. (A) CFUs in lungs were analyzed by culturing lung
homogenates and enumerating the bacteria. Each bar represent the median (CFU/lung for each group of mice). Comparisons among groups were determined by
one-way ANOVA followed by Holm-Sidak’s multiple comparison test. A value of p < 0.05 was considered statistically significant. *p < 0.05 and **p < 0.01. (B) The
presence of Mtb in spleens was analyzed in all the studied groups. The graph shows the percentage of mice displaying bacteria in their spleens. Comparisons with
control groups were determined by Fisher’s exact test, #p < 0.05. A representative example of three assays is shown.
most common form of the disease in adults and teenagers (World
Health Organization, 2019), BCG confers 59% of protection in
children (Mangtani et al., 2014). Furthermore, BCG does not
protect after 10–15 years of vaccination in endemic countries
(Sterne et al., 1998; Abubakar et al., 2013). Thus, in order to
eradicate TB, new vaccines conferring protection during the
whole life of the individual are required.
Preventive vaccines against TB can be classified into four
broad categories: viable whole-cell vaccines (such as VPM1002,
MTBVAC or BCG revaccination), inactivated whole-cell vaccines
(such as VaccaeTM, RUTI, DAR-901, MIP, or AEC/BCO2),
protein subunit vaccine (such as ID93/GLA-SE, H56:IC31,
M72/AS01E, or GamTBVac), and viral-vectored vaccines (such as
ChAdOx185A-MVA85A, TB/FLU-04L, or Ad5Ag85A) (Home—
ClinicalTrials.gov1). Among these 15 vaccine candidates in
clinical phase, the adjuvants employed include GLA-SE, AS01E,
IC31, and CpG plus alum salt-based adjuvant or DEAE-dextran
core. All of the mentioned adjuvants are included in protein
subunits vaccines formulations, and there are currently no
clinical trials reports using DNA vaccines. Given the importance
of IL-12 during the immune response of the host against Mtb
infection, its use as a vaccine adjuvant has been previously
proposed (Ha et al., 2006; Yoshida et al., 2006).
IL-12 helps naïve T cells to switch to Th1 lymphocytes and
increases T cells cytotoxicity. The use of IL-12 as an adjuvant
has been investigated in vaccines against several pathogens
(Chow et al., 1998; Gherardi et al., 2000, 2001, 2003; Du
et al., 2003; Tapia et al., 2003; Abaitua et al., 2006; Rodríguez
et al., 2012; Kalams et al., 2013; Maeto et al., 2014; Elizaga
et al., 2018). However, the study of IL-12 as an adjuvant in
TB vaccines has been scarcely explored. This might be partly
because recombinant IL-12 is quickly removed and inactivated
in vivo (Ha et al., 2006). In fact, to avoid IL-12 removal, Ha
et al. (2006) encapsulated recombinant IL-12 in microspheres to
achieve its sustained local expression. The authors showed that
the combination of IL-12 plus AS01B adjuvants in a TB subunit
vaccine-induced mice immunity and protection against Mtb
challenge. In addition, Yoshida et al. used the hemagglutinating
virus of Japan (HVJ)-liposome method to encapsulate mouse
IL-12 expression vector (mIL-12). Then, the authors immunized
mice with mIL-12/HVJ plus DNA expressing IgHsp65 (Yoshida
et al., 2006). However, no significant differences in the number of
CFU per lung were detected between the mIL-12/HVJ (control)
and the IgHsp65+mIL-12/HVJ groups (Yoshida et al., 2006).
Therefore, the protection described by these authors would not
be associated with the host immune response against Hsp65
antigen immunization.
Cytokines are crucial initiators and regulators of the immune
response. In TB, key effectors related to host protection
include IL-12 and IFN-γ (North and Jung, 2004; Cooper,
2009). IL-12 displays multiple biological functions in immunity
modulation, linking the early innate immune response with the
subsequent antigen-specific adaptive immunity (Hamza et al.,
2010). Accordingly, it has been demonstrated that mice deficient
in IL-12 were more susceptible to Mtb infection than wild-type
animals (Hölscher et al., 2001). Moreover, IL-12 is critical for
activation of CD4+T cells, leading to the protective Th1 response
that promotes IFN-γ secretion by T lymphocytes. Therefore,
given the crucial role of IL-12 in TB infection, in this study, we
evaluated the incorporation of plasmid DNA encoding murine
IL-12 during Ag85A DNA prime followed by a heterologous
boost with MVA85A. In line with our work, other authors have
previously evaluated the modulation of the response induced by
DNA vaccines co-injected with pro-inflammatory cytokines in
individual vectors (Kim et al., 1998; Tapia et al., 2003; Rodríguez
et al., 2012). Initially, we analyzed the adjuvant effect of IL-12
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DNA on Ag85A DNA immunization as compared to mice that
received Ag85A DNA alone (Figures 2A,C). We observed that
IL-12 DNA co-administration significantly increased both the
levels of IgG and IFN-γ in response to Ag85A. Furthermore,
whenmice received a boost ofMVA85A, even higher levels of IgG
and IFN-γ against Ag85A were detected (Figure 2). Moreover,
the IFN-γ secretion augment was a reflection of the increase of
CD4+ and CD8+ IFN-γ producing lymphocytes (Figures 3B,C).
In addition, the co-administration of IL-12 adjuvant induced
the expansion of a higher proportion of cytotoxic CD8T cells
(Figures 3D,E). Even more, mice that received a vaccination
scheme augmenting the host immune response showed the
highest protection against Mtb challenge. However, in order to
further analyze bacterial load, future studies including staining
of Mtb (such as acid-fast staining) in tissue samples should
be performed.
In this study, we employed Ag85A and IL-12 in different
vectors. We had previously used this same strategy using either
IL-12 or GM-CSF in trans-expression, with optimal results
(Rodríguez et al., 2012). Considering that IL-12 is a soluble
mediator required in themicroenvironment, the use of individual
vectors might have a positive effect without the need to be
expressed in the same cell as the antigen. Other authors have used
different cytokines expressed by DNA in trans as adjuvants in
DNA vaccines (Hanlon et al., 2001; Tapia et al., 2003; Abaitua
et al., 2006). However, in the context of TB disease, Sun et al.
(2017) have previously employed the cis-expression of Ag85A
and IL-15 with encouraging results.
During clinical trials, MVA85A was commonly administered
by the intradermal route (Tameris et al., 2013; Ndiaye
et al., 2015). Nevertheless, when Tchilian et al. (2009) used
the intradermal route to apply MVA85A as a BCG boost
in the murine model, they were unable to observe any
improved effect beyond the protection conferred by BCG.
Furthermore, MVA85A immunogenicity and efficacy in mice
have been demonstrated using nasal (Goonetilleke et al.,
2003) or intravenous (McShane et al., 2002; Romano et al.,
2006) routes. Thus, since immunization with DNA vaccines is
usually performed by i.m. route while MVA boost is normally
achieved by i.p. route (Rodríguez et al., 2012; Pérez et al.,
2020) we used those immunization routes in our mice model.
Importantly, this immunization strategy using an adjuvant plus
a viral vector was used with the ultimate aim of eliciting
efficient humoral and cellular immune responses against the
selected antigen.
Several cytokines have a critical function in the immune
response of the host against Mtb (Domingo-Gonzalez et al.,
2016). The central role of IFN-γ in the immune response
against Mtb infection has been widely demonstrated both in
mouse models (Flynn et al., 1993) and humans. Accordingly,
we previously reported that TB patients with a weak immune
response against Mtb and impaired IFN-γ production displayed
the most severe disease (Pasquinelli et al., 2004). Moreover,
we demonstrated that IFN-γ promotes autophagy in infected
monocytes from TB patients contributing to the elimination
of Mtb (Tateosian et al., 2017). In the present work, we
focused on IFN-γ determination, although the role of other
crucial cytokines in TB infection should be evaluated in the
future. In fact, Sakai et al. reported that IFN-γ from CD4+
T lymphocytes were responsible for only one third of the
total anti-bacterial effects of CD4+ T cells in the lungs (Sakai
et al., 2016). Furthermore, increasing IFN-γ production led
to the early death of the host in mice infection models
(Sakai et al., 2016). Additionally, it has been reported that a
polyfunctional Mtb specific CD4+ T cell immune response is
required for protective pulmonary immunity during TB (Wu
et al., 2017). In fact, IFN-γ could be a part of the response
of polyfunctional Mtb specific lymphocytes (IFN-γ/IL-2/IL-
17/TNF-α) but the role of the other cytokines in the immune
response of the host against Mtb has to be considered as well.
Nevertheless, Beveridge et al. (2007) reported that MVA85A
immunization induced polyfunctional CD4+ T lymphocytes
producing TNF-α, IFN-γ, and IL-2 in humans, but no increase
in protection was observed. Moreover, the development of
phase I of the AERAS-402 candidate vaccine (a recombinant
adenovirus which expresses theMtb antigens Ag85A, Ag85B, and
TB10.4) demonstrated that polyfunctional T cell response were
not directly associated with the ability of these lymphocytes to
identify Mtb infected cells (Nyendak et al., 2016). In any case,
the role of polyfunctional T cells in our present model should be
investigated in future experiments.
The adjuvant potential of IL-12 to induce cytotoxicity has been
previously demonstrated (Okada et al., 1997; Tsuji et al., 1997;
Belyakov et al., 1998; Tatsumi et al., 2001; Moore et al., 2002;
Matsui et al., 2003). Mtb can infect epithelial and endothelial
cells, and CD8 lymphocytes (together with NK cells) have the
ability to eliminate infected cells. Furthermore, cytotoxic CD8
cells have a critical role in killing infected macrophages during
TB. Our findings showed that immunization with IL-12 and
Ag85A as DNA plus a boost of MVA85A induced a significant
increment in the percentage of Ag85A specific CD8+ CD107a/b+
cells (Figure 3D).
Immune response against Mtb is complex, but the
participation of macrophages and T lymphocytes in the
defense of the host against the pathogen has been extensively
demonstrated (Chai et al., 2020). In contrast, the role of
humoral immunity in the fight against Mtb has been ignored
for many years. For this reason, most vaccine candidates focus
on the development of appropriate cellular immune responses
against Mtb. Nevertheless, there are studies demonstrating that
polyfunctional and neutralizing antibodies might potentiate
humoral effector functions of macrophages and NK cells
(Choreño-Parra et al., 2020). By evaluating the production
of antibodies, significantly higher levels of anti-Ag85A IgG
were detected in mice that received three-doses of Ag85A
DNA plus IL-12 DNA as compared to mice immunized with
three-doses of Ag85A DNA alone (Figure 2B). Moreover,
we observed a significant increase in serum IgG against
Ag85A in mice immunized with pCI-Ag85A and MVA85A
that also received pCI-IL12 as an adjuvant (Figure 2D).
These results are in line with previous reports showing
that administration of IL-12 as an adjuvant improves the
humoral response of vaccine candidates (McKnight et al.,
1994; Germann et al., 1995; Metzger et al., 1996). Importantly,
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a retrospective analysis in BCG-vaccinated children who
received MVA85A showed that elevated anti-Ag85A IgG
levels at 28 days after MVA85A boost, reduced the risk
of TB development (Fletcher et al., 2016). Therefore an
association between the levels of antibodies against Ag85A
and the probability of Mtb disease in infants was suggested
(Fletcher et al., 2016).
Cytokines present in the environment impact on maturation
of DCs by modulating their functions during the maturation
and migration processes (Banchereau and Steinman, 1998;
Fukao et al., 2001). DCs are professional antigen-presentation
cells and their main functions are antigen capture and
processing, migration to secondary lymphoid organs, and T
cell priming. It has been demonstrated that DCs express a
single class of high-affinity IL-12R (functionally distinct from
those in T and NK cells) that upon binding IL-12 activates
members of the NF-κB family and leads to endogenous
IL-12 production (Grohmann et al., 1998). Therefore, we
hypothesized that in our model, the adjuvant effect of IL-
12 DNA on the immunogenicity of the DNA vaccine might
be related to the local production of IL-12 by a mechanism
similar to the one described by Grohmann et al. In fact, IL-
12 produced by IL-12 DNA at the site of injection would
induce DCs to secrete more IL-12 eliciting a Th1 profile and
activating CD8 cells at the draining lymph node. Furthermore,
there is evidence that IL-12 and antigen presentation can
be produced by different cells (Bianchi et al., 1999). On
the other hand, CDs and monocytes were shown to be
capable of producing IFN-γ when cultured in the presence
of IL-12, playing an important role in innate immunity
and subsequent T helper cell type 1 development in vivo
(Ohteki et al., 1999).
Taken together, our results demonstrate the ability of IL-12
DNA to improve the humoral and cellular immune responses
against Ag85A induced by DNA/MVA85A immunization. Thus,
IL-12 DNA might be considered as a tool for designing vaccine
strategies to controlMtb infection.
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